论文部分内容阅读
“吸收窗”(Absorption window)概念可简明地解释某些药物经口服途径吸收不完全。这类药物并非在整个胃肠道内吸收,而仅在某一特定的节段吸收,因而在整个剂量被吸收前,由于胃肠道蠕动,药物可能离开该部位。Wagner 于1974年提出“吸收窗”术语,并以“窗口效应”(Window effect)假说来解释地高辛生物利用度低的原因。先前的实验结果表明,地高辛仅在人体小肠上部迅速吸收,从而部分证实此假说。次年,Wagner 阐述了“吸收窗”的药物动力学模型。近年来“吸收窗”已成为讨论缓释剂型有效性的重要议题。在爱丁堡(1979)
The Absorption window concept concisely explains the incomplete absorption of certain drugs by the oral route. Such drugs are not absorbed throughout the GI tract but absorbed only in a particular segment, so that the drug may leave the site before the entire dose is absorbed due to gastrointestinal motility. Wagner proposed the term “absorption window” in 1974 and explained the reason for the low bioavailability of digoxin with the “Window effect” hypothesis. Previous experimental results show that digoxin is only rapidly absorbed in the upper part of the human small intestine, thus partially confirming this hypothesis. The following year, Wagner elaborated the “absorption window” pharmacokinetic model. In recent years, “absorption window” has become an important topic to discuss the effectiveness of sustained release formulations. In Edinburgh (1979)